The Swiss Pharmaceutical Giant Roche announced on Wednesday, July 23, after having obtained approval in the European Union of a new breast cancer treatment, but also the marking of CE for a diagnosis test of Alzheimer’s disease.
The European Commission has given Inava -File light, marketed under the name of Itavebi for an advanced or metastatic form of breast cancer, in association with Palbociclib and Fulvestrant, said the Swiss group in a press release. The authorization was based on a phase III study that demonstrated a 57% reduction in the risk of worsening disease or death.
Approved last October in the United States, this treatment is intended for a very common subtype of the disease. It is indicated for breast cancer “positive for hormonal receptors (HR positive) and negative for receptor 2 of the human epidermal growth factor (negative her2)” and is used “when breast cancer has a change in the PIK3CA gene”, specifies the Swiss site, the Swiss health authority, which has its authorized side at the end of January.
Soon a blood analysis for Alzheimer’s
In a separate press release, Roche, which is also active in the diagnoses, announced that it has obtained the marking of European compliance for a test of detection of Alzheimer’s disease.
Developed with the American laboratory Eli Lilly, this blood test was designed to allow doctors to rule out the fact that it is Alzheimer’s disease when patients have symptoms of cognitive deterioration. Called ELECTUSS PTAU181, identify one of the biomarkers of the disease. It allows doctors to establish whether or not the cause of cognitive deterioration, and if other tests are necessary or not, and therefore, avoid unnecessary and invasive tests.
In the press release, Roche emphasizes that up to 75% of people have symptoms without being diagnosed and that patients are often necessary before patients are diagnosed after the disease appears.
Roche must publish its half -year results on Thursday. The world number one in Oncology has several treatments against breast cancer, including Perjeta and Phesgo. In addition to its pharmaceutical division, it is also based on a division specialized in diagnostic tests that contributed to almost a quarter of its turnover in 2024.
Source: BFM TV
